Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
1. EBS secured a contract modification for CNJ-016® with ASPR. 2. The contract enhances smallpox preparedness through additional doses of VIGIV. 3. The modification reinforces EBS's partnership with the U.S. government. 4. Emergent continues to supply vital medical countermeasures domestically and globally. 5. VIGIV is crucial for treating complications from smallpox vaccination.